Abstract:Background: Increased HBV-replication and/or intracellular HBsAgretention favor the onset of hepatocellular-carcinoma (HCC).Here, we define mutations in pre-S1/Pre-S2/S-gene correlated with HBVinduced HCC in-vivo, and investigate their impact on HBsAgretention and secretion in an in-vitro model.Methods: Sixty-seven HBV chronically-infected patients (74.6% genotype-D; 20.9% genotype-A; and 4.5% others), 19 of them with HCC and 48 asymptomatic patients (as control), were analyzed.Association of mutations with HCC was assessed by Fisher-test with Benjamini-Hochberg for multiple-comparison correction.Mutants were constructed by site-directed mutagenesis and expressed in HuH7-hepatocytes using the expression-vectors pCHD9 with fulllength HBV-genome (for mutations S98T S1 -P203Q S -S210R S ) and pCHsAgD with pre-S1/pre-S2/S-gene (for N40I S -K141N S ).After 72h quantitative-HBsAg was tested in cell-supernatants and in celllysates using Abbott-Architect assay.Results: Novel mutations in pre-S1 (S98T S1 ), and S region (N40I S -K141N S -P203Q S -S210R S ) correlate with HCC (P = 10 -2 to 10 -4 ) invivo.19/19 patients with HCC carry ≥1 of them (range-prevalence: 12.5% to 37.5%), while these mutations are absent (0/48 for N40I S ) or occurring with low frequency (1.9% for K141N S -P203Q S , 4.7% for S98T S1, 7.5% for S210R S ) in non-HCC patients.Strong correlations are observed for P203Q S +S210R S (phi=0.83)and N40I S +K141N S (phi=0.56).S98T S1 corresponds to the nucleotide codon 3175-3177 of HBVgenome localized in the promoter of the middle S-protein.In in-vitro experiments, its presence determines a 3.71 foldincrease in HBsAg-levels released in supernatants (S98T: 127.47[sd±53.45]IU/ml;WT: 34.40[sd±13.28]IU/ml,P = 0.00016).An opposite scenario is observed for P203Q S +S210R S , localized in the membrane-embedded C-terminal domain critical for HBsAg-secretion.This couple of mutations drastically decreases supernatant HBsAg-levels compared to P203Q and S210R alone, and to wild-type (P203Q+S210R: 9.42[sd±1.35]IU/ml;P203Q: 26.85[sd±13.01]IU/ml;S210R: 25.95[sd±8.82]IU/ml;WT: 34.40[sd:±13.28]IU/ml,P < 0.01).P203Q+S210R also decrease the ratio of supernatant to lysate HBsAg compared to wild-type (0.61 for P203Q+S210R versus 1.20 for wild-type), supporting their ability in inducing HBsAg intracellular-retention.Similarly, K141N determines a 52%-reduction of supernatant HBsAglevels compared to wild-type (K141N: 13.43[sd±9.68]IU/ml;WT: 28.25[sd±13.12]IU/ml.This reduction is greater when K141N is co-present with N40I (K141N+N40I: 4.67[sd±2.31]IU/ml,P = 0.012).K141N introduces a new N-linked glycosylation-site, while N40I resides in the cytosolic-loop involved in HBsAg-secretion.Conclusions: Key genetic-elements in pre-S1/pre-S2/S-gene correlate with HCC by inducing intracellular HBsAg-retention and/or by potentially altering the production of mRNAs for S-gene.Their detection may help identifying patients at higher HCC-risk.

Naturally Occurring Deletion/Insertion Mutations Within Hbv Whole Genome Sequences in Hbeag-Positive Chronic Hepatitis B Patients Are Correlated with Baseline Serum Hbsag and Hbeag Levels and Might Predict A Shorter Interval to Hbeag Loss and Seroconversion During Antiviral Treatment

HBcrAg, Pg RNA and HBsAg Dynamically Supervise the Seroconversion of HBsAg with Anti-Viral Therapy "loss of HBsAg" Maybe Not a Good End-Point of Anti-Viral Therapy

Baseline Quantitative Hepatitis B Core Antibody Titre Alone Strongly Predicts HBeAg Seroconversion Across Chronic Hepatitis B Patients Treated with Peginterferon or Nucleos(t)ide Analogues.

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs.

Evolutionary analysis of pre S/S mutations in HBeAg-negative chronic hepatitis B with HBsAg <100 IU/ml

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B with HBsAg < 100 IU/ml

The Presence of Baseline HBsAb-Specific B Cells Can Predict HBsAg or HBeAg seroconversion of Chronic Hepatitis B on treatment

Novel Approach to Identifying the Hepatitis B Virus Pre-S Deletions Associated with Hepatocellular Carcinoma

Comparative analysis of HBV pre-S deletion in chronically HBV-infected patients with different illness categories

Naturally Occurring 5' Pres1 Deletions Markedly Enhance Replication And Infectivity Of Hbv Genotype B And Genotype C

Concurrent HBsAg and anti-HBs induced by a preS deletion mutant in a chronic hepatitis B patient

Hepatitis B Virus Mutations Associated with in Situ Expression of Hepatitis B Core Antigen, Viral Load and Prognosis in Chronic Hepatitis B Patients

432 TRANSFER OF HEPATITIS B SURFACE MARKERS AND HBVDNA FROM HEPATITIS B SURFACE ANTIGEN POSITIVE MOTHERS TO THEIR OFFSPRING

Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase

Prevalence of Basal Core Promoter and Precore Mutations in Chinese Chronic Hepatitis B Patients and Correlation with Serum HBeAG Titers

Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment

Capabilities of Hepatitis B Surface Antigen Are Divergent from Hepatitis B Virus DNA in Delimiting Natural History Phases of Chronic Hepatitis B Virus Infection

Correlation of Hepatitis B Virus (hbv) Genotypes and Mutations in Basal Core Promoter/Precore with Clinical Features of Chronic Hbv Infection